CD33 and neoplasm: Allo15CAR33-NKT cells are expected to target myeloid malignancy tumor cells through multiple surface receptors, including CAR33-mediated recognition of CD33, NKT TCR-mediated recognition of CD1d, and NKR-mediated recognition of NK ligands.